Prognostic Impact of Cytogenetic Evolution on the Outcome of Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia in Nonremission: A Single-Institute Analysis of 212 Recipients

•Effect of acute myeloid leukemia karyotype on the outcomes of allogeneic stem cell transplantation was tested.•Cytogenetic evolution affects prognosis after allogeneic stem cell transplantation. Recent progress in genetic analysis technology has helped researchers understand the pathogenesis of acu...

Full description

Saved in:
Bibliographic Details
Published in:Biology of blood and marrow transplantation 2020-12, Vol.26 (12), p.2262-2270
Main Authors: Yuasa, Mitsuhiro, Yamamoto, Hisashi, Mitsuki, Takashi, Kageyama, Kosei, Kaji, Daisuke, Taya, Yuki, Nishida, Aya, Ishiwata, Kazuya, Takagi, Shinsuke, Yamamoto, Go, Asano-Mori, Yuki, Wake, Atsushi, Koike, Yukako, Makino, Shigeyoshi, Uchida, Naoyuki, Taniguchi, Shuichi
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Allogeneic stem cell transplantation
Complex karyotype
Cytogenetic evolution
Karyotype
Monosomal karyotype
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Effect of acute myeloid leukemia karyotype on the outcomes of allogeneic stem cell transplantation was tested.•Cytogenetic evolution affects prognosis after allogeneic stem cell transplantation. Recent progress in genetic analysis technology has helped researchers understand the pathogenesis of acute myeloid leukemia (AML). Considering this progress, AML karyotype is still one of the most significant prognostic factors that provides risk-adapted treatment approaches. Karyotype changes during treatment have been observed at times, but their prognostic impact is sparse, especially on allogeneic stem cell transplantation (allo-SCT). Here, we retrospectively investigated the effect of chromosomal changes between diagnosis and pretransplantation on the prognosis of allo-SCT by analyzing the outcomes of 212 consecutive patients who underwent allo-SCT for the first time at Toranomon Hospital, Tokyo, Japan, between 2008 and 2018. Cytogenetic abnormalities at diagnosis and pretransplantation were categorized based on the 2017 European Leukemia Net risk stratification. Genetic abnormalities such as FLT3-ITD and NPM1 were not considered in this study due to lack of genetic information in most patients. We defined cytogenetic evolution as chromosomal changes classified from lower category to higher category. Seventeen patients (8%) had cytogenetic evolution between diagnosis and pretransplantation, and they showed a significantly worse relapse rate than those who were categorized in the intermediate group based on the karyotype at diagnosis (3-year confidence interval [CI] of relapse, 57.4% versus 24.9%; P < .01). In multivariate analysis, cytogenetic evolution before allo-SCT had a significant impact on the CI of relapse (hazard ratio [HR], 3.89; CI, 1.75 to 8.67; P < .01), as well as the high score of the hematopoietic cell transplantation-specific comorbidity index (HR, 0.54; CI, 0.31 to 0.94; P = .03), but had no significant impact on overall survival or nonrelapse mortality. These results indicate that cytogenetic evolution has a significant impact after allo-SCT and should be considered during AML treatment.
ISSN:1083-8791
1523-6536
DOI:10.1016/j.bbmt.2020.08.026